Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Genes, ras
  • Lung Neoplasms
  • Mutation
  • Neoplasm Recurrence, Local
  • Receptor, Epidermal Growth Factor

abstract

  • Among patients with KRAS-mutant lung adenocarcinomas, stage of disease at diagnosis was associated with OS from the time of diagnosis of recurrent/metastatic disease. In multivariable analyses, in both patients with EGFR-mutant and KRAS-mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival. Stage at diagnosis is a prognostic variable that should be accounted for in prospective studies in patients with metastatic lung adenocarcinomas.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4783794

Digital Object Identifier (DOI)

  • 10.1002/cncr.29313

PubMed ID

  • 25781862

Additional Document Info

start page

  • 2078

end page

  • 82

volume

  • 121

number

  • 12